This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A third discussion of the clinical landscape of Hereditary Angioedema, with a focus on the phase 1/2 results of Intellia's CRISPR treatment, NTLA-2002

Ticker(s): NTLA, BCRX, IONS, TAK

Who's the expert?

Institution: ProHealthcare

  • Allergist treating 13 patients with HAE
  • Medical education at Emory University, St. Jude’s Children’s Hospital, the University of Tennessee, and the Albert Einstein College of Medicine New York.
  • Provides testing for environmental and food allergies, pulmonary function testing, laboratory evaluation of immunity, and general allergy and immune consultations.

Interview Goal
To speak with a physician who manages patients with hereditary angiodema in order to discuss the standard of care and the phase 3 results of Intellia's potential CRISPR treatment.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.